Leiden Dworak - 21 Jul 2023 Form 4 Insider Report for TScan Therapeutics, Inc. (TCRX)

Role
Chief Accounting Officer
Signature
/s/ Leiden Dworak
Issuer symbol
TCRX
Transactions as of
21 Jul 2023
Net transactions value
$0
Form type
4
Filing time
24 Jul 2023, 19:39:09 UTC
Next filing
11 Feb 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCRX Stock Option (Right to Buy) Award $0 +25,000 $0.000000 25,000 21 Jul 2023 Voting Common Stock 25,000 $2.23 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of July 21, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer.